Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Zanamivir for Influenza A and B in China
NCT01459081Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2011
- Primary completion
- Dec 2012
- Countries
- 1
- Sponsor
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Drugs
- zanamivir
- Conditions
- Influenza A (IAV)influenza B
01
Overview
Phase 3, randomised, double-blind trial in Influenza A (IAV) and influenza B comparing Zanamivir with Placebo (2 arms). Primary endpoint: Time to alleviation of clinically important symptoms at 21 days. Started Oct 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Zanamivir
Zanamivir 10 mg inhaled twice daily for 5 days
Placebo
Placebo inhaled twice daily for 5 days
03
Who it enrols
Patients with fever >38.0C and influenza-like symptoms starting within 48 hours. Excludes patients with respiratory diseases (asthma, COPD), liver/renal impairment, recent flu vaccination, or HIV.
04
Endpoints
Primary
Time to alleviation of clinically important symptoms
Secondary
Symptom score AUC
Mean symptom scores
The use of relief medication
Beyond the preview
Go deeper on NCT01459081.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01459081.